

Special Issue

Antibiotic Strategy for Ventilator-Associated Respiratory Infections

Message from the Guest Editor

Ventilator-associated lower respiratory tract (LRT) infections remain a major challenge in intensive care. Ventilator-associated pneumonia (VAP) is a leading nosocomial infection in critically ill patients, associated with prolonged ventilation, longer hospital stays, higher costs, and increased mortality. Important gaps remain in optimal diagnosis, the value of molecular tests, the role of prior colonization in guiding empirical therapy, and the preservation of anaerobic flora.

The clinical relevance and treatment of ventilator-associated tracheobronchitis (VAT) remain controversial, as its criteria overlap with VAP and complicate clinical decisions. Biomarkers such as procalcitonin have limited ability to distinguish VAT, VAP, and colonization. Rising multidrug resistance further complicates treatment duration and the choice between monotherapy and combination therapy.

We welcome original research, reviews, and methodological studies on ventilator-associated respiratory infections in critically ill patients.

Guest Editor

Dr. Fernando Martínez-Sagasti

Department of Intensive Care Medicine, University Hospital Clínico San Carlos, 28040 Madrid, Spain

Deadline for manuscript submissions

30 June 2026



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/268140

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)